Recombinant lymphocytic choriomeningitis virus-based vaccine vector protects type I interferon receptor deficient mice from viral challenge

Królik, Michał; Csepregi, Lucia; Hartmann, Fabienne; Engetschwiler, Céline; Flatz, Lukas

doi:10.1016/j.vaccine.2021.01.047

Cited by 4 publications

(6 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…are carried out in the cases of infectious outbreak. Reverse genetically engineered recombinant LCMV (rLCMV) is an important candidate for the development of vector-based vaccines [45]. Schmidt et al (2020) constructed a new vaccine TT1-E7E6 based on replicating attenuated LCMV [46].…”

Section: Lymphocytic Choriomeningitis Virus Infection-what Is Done An...mentioning

confidence: 99%

Lymphocytic Choriomeningitis Virus infection

Gladnishka,

Trifonova,

Ivanova

et al. 2024

Probl Infect Parasit Dis

View full text Add to dashboard Cite

Background: Lymphocytic choriomeningitis virus (LHMV) infection is a neglected rodent-borne zoonotic infection but it is found all over the world because of the cosmopolitan distribution of its reservoirs. The diagnostic of this disease is not widely applied that is why it has been underreported. The aim of this study is to investigate infection with LCMV in hospitalized patients in 2015-2022 in Bulgaria and to analyse the data compared to the worldwide data available in this field of research. Materials/methods: A total of 66 serum samples and 25 cerebrospinal fluid (CSF) samples from 73 patients with suspected LCMV infection from different hospitals in Bulgaria were collected. All samples were tested with a commercial enzyme-linked immunosorbent assay (Human LCMV-Ab ELISA, SSBT, China), based on the principle of double-antibody sandwich technique to detect Human LCMV-Antibody. Results: A total of 11/91 (12.09%) positive samples were found in 5 males and 6 females throughout the study period. The positive samples were from patients from the cities: Sofia, Stara Zagora, Montana. A total of 3/25 (12%) positive samples were from CSF samples and 8/66 positive samples (12.12%) were from serum samples. Conclusions: It’s found that this infection occurs in our country and should not be underestimated, due to the possible severe neurological course and the danger of fetal damage in pregnant women. The diagnosis of LCMV infection is based on previous experience, placed in the light of the continuous introduction of new more sensitive and specific approaches.

show abstract

Section: Lymphocytic Choriomeningitis Virus Infection-what Is Done An...mentioning

confidence: 99%

Lymphocytic Choriomeningitis Virus infection

Gladnishka,

Trifonova,

Ivanova

et al. 2024

Probl Infect Parasit Dis

View full text Add to dashboard Cite

show abstract

“…Reverse genetically altered recombinant LCMV (rLCMV), in addition to serving as a significant research model in immunology, is a significant potential for the creation of vector-based vaccines. In immunosuppressed mice, who are deficient in a functioning type I IFN receptor, Krolik et al (2021) recently published the findings of a safety and effectiveness examination of a non-replicating rLCMV vector producing ovalbumin as a model antigen. When mice was immunised, this resulted in the development of multifunctional cytotoxic CD8+ T-cells and memory T-cells, which cleared the rLCMVovalbumin vector 7 days after vaccination (Krolik et al 2021).…”

Section: Vaccine Research In Lcmvmentioning

confidence: 99%

“…In immunosuppressed mice, who are deficient in a functioning type I IFN receptor, Krolik et al (2021) recently published the findings of a safety and effectiveness examination of a non-replicating rLCMV vector producing ovalbumin as a model antigen. When mice was immunised, this resulted in the development of multifunctional cytotoxic CD8+ T-cells and memory T-cells, which cleared the rLCMVovalbumin vector 7 days after vaccination (Krolik et al 2021). Non-replicating rLCMV-based vectors appear to be a good choice for vaccine development due to the rLCMV viral vector's outstanding safety profile and retained effectiveness in immunocompromised animals.…”

Section: Vaccine Research In Lcmvmentioning

confidence: 99%

Epidemiological Trends of Lymphochoriomeningitis Virus Infection

2023

IJAB

View full text Add to dashboard Cite

Lymphocytic choriomeningitis virus (LCMV) a member of family Arenaviridae genus Mammarenavirus, discovered in 1933 from a patient with meningoencephalitis, persists as a significant zoonotic threat, primarily harbored by house mice and linked to aseptic meningitis in humans. Its global impact ranges from mild flu-like symptoms to severe neurological complications, particularly perilous in immunocompromised individuals and pregnant women, leading to fetal abnormalities and mortality. Human transmission primarily occurs through contact with rodents or exposure to contaminated aerosols, highlighting house mice (Mus musculus), especially persistently infected ones, as key agents in human infections. M. musculus and Mus domesticus are the natural and reservoir host of LCMV virus. Except for vertical transmission from infected pregnant women to foetus and organ donation, there is no evidence of human-to-human transfer. The LCMV targets the endothelial and lymphatic cells and replicate there or settle down in lymphatic tissues like spleen or lymph nodes and further replicate there leading to viremia to various organs. In the 1950s virus has been detected about 8% of the patients suffering with neuroinvasive disease. Diagnosis remains challenging due to limited diagnostic tools, Serological tests like IFA and EIA target immunoglobulin M and G, RT-PCR, and viral isolation being employed. Therapeutic options, notably ribavirin, show promise but remain limited, while ongoing vaccine research investigates candidates like reverse genetically altered recombinant LCMV and replicating LCMV-based vectors. LCMV's global prevalence, though constrained by diagnostic limitations, underscores its continued public health impact, necessitating sustained research into diagnostics, treatments, and vaccines to mitigate its multifaceted threats.

show abstract

“…In addition to an important role as a research model in immunology, reverse geneticallyengineered recombinant LCMV (rLCMV) is an important candidate in the development of vector-based vaccines. Krolik et al (2021) recently reported results of safety and efficacy analysis of a non-replicating rLCMV vector expressing ovalbumin as a model antigen in immunocompromised Ifnar−/− mice that lacks a functional type I IFN receptor. Immunization of Ifnar−/− mice induced differentiation of multifunctional cytotoxic CD8+ T-cells and memory T-cells, leading to the clearance of rLCMV-ovalbumin vector within 7 days post-vaccination [109].…”

Section: Lcmv In Vaccine Researchmentioning

confidence: 99%

“…Krolik et al (2021) recently reported results of safety and efficacy analysis of a non-replicating rLCMV vector expressing ovalbumin as a model antigen in immunocompromised Ifnar−/− mice that lacks a functional type I IFN receptor. Immunization of Ifnar−/− mice induced differentiation of multifunctional cytotoxic CD8+ T-cells and memory T-cells, leading to the clearance of rLCMV-ovalbumin vector within 7 days post-vaccination [109]. An excellent safety profile of the rLCMV viral vector derived from Clone 13 in combination with maintained efficacy in immunocompromised hosts suggest that non-replicating rLCMV-based vectors represent a promising candidate for vaccine development.…”

Section: Lcmv In Vaccine Researchmentioning

confidence: 99%

Lymphocytic Choriomeningitis—Emerging Trends of a Neglected Virus: A Narrative Review

et al. 2021

View full text Add to dashboard Cite

Lymphocytic choriomeningitis virus (LCMV) is a neglected rodent-borne zoonotic virus distributed worldwide. Since serologic assays are limited to several laboratories, the disease has been underreported, often making it difficult to determine incidence and seroprevalence rates. Although human clinical cases are rarely recorded, LCMV remains an important cause of meningitis in humans. In addition, a fatal donor-derived LCMV infection in several clusters of solid organ transplant recipients further highlighted a pathogenic potential and clinical significance of this virus. In the transplant populations, abnormalities of the central nervous system were also found, but were overshadowed by the systemic illness resembling the Lassa hemorrhagic fever. LCMV is also an emerging fetal teratogen. Hydrocephalus, periventricular calcifications and chorioretinitis are the predominant characteristics of congenital LCMV infection, occurring in 87.5% of cases. Mortality in congenitally infected children is about 35%, while 70% of them show long-term neurologic sequelae. Clinicians should be aware of the risks posed by LCMV and should consider the virus in the differential diagnosis of aseptic meningitis, especially in patients who reported contact with rodents. Furthermore, LCMV should be considered in infants and children with unexplained hydrocephalus, intracerebral calcifications and chorioretinitis. Despite intensive interdisciplinary research efforts, efficient antiviral therapy for LCMV infection is still not available.

show abstract

Recombinant lymphocytic choriomeningitis virus-based vaccine vector protects type I interferon receptor deficient mice from viral challenge

Cited by 4 publications

References 37 publications

Lymphocytic Choriomeningitis Virus infection

Lymphocytic Choriomeningitis Virus infection

Epidemiological Trends of Lymphochoriomeningitis Virus Infection

Lymphocytic Choriomeningitis—Emerging Trends of a Neglected Virus: A Narrative Review

Contact Info

Product

Resources

About